JPRN-jRCT2031220113招募中2 期
Observational study of children with achondroplasia
onaka Yosuke0 个研究点目标入组 14 人开始时间: 2022年6月8日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- >= 5age old 至 <= 14age old（—）
- 性别
- All
入选标准
- •(1) Able to obtain written informed consent from surrogate decision maker (parents, relatives or legal representative) before study entry
- •Able to obtain written informed assent from the patient after explaining the contents of this trial in the assent document (if possible)
- •(2) Has achondroplasia, diagnosed by genetic diagnosis
- •(3) Aged 5 to 14 years, inclusive, at study entry
- •(4) Able to lead a normal life without assistance
- •(5) Able to perform all the tests described in the protocol ,judged by Investigator
排除标准
- •(1) Has short stature condition other than achondroplasia
- •(2) Has congenital diseases other than achondroplasia
- •(3) Has history of treatment with growth hormone or VOXZOGO within 12 weeks before study entry
- •(4) Has history of limb-lengthening surgery
- •(5) With a closed growth plate
- •(6) Has any of the following disorders that require surgical treatment on MRI or CT scans, or has clinically significant neurological symptoms or obstructive sleep apnea syndrome caused by these disorders: foramen magnum stenosis, spinal stenosis, hydrocephalus, spinal cord and cauda equina compression, etc (However, patients who have undergone surgical treatment for these disorders at least 26 weeks (6 months) before study entry and have no clinical problems can be enrolled)
- •(7) Has a history of allergies against the following products containing RBM-007 components (e.g., nucleic acid, polyethylene glycol, mannitol): prescribed medicines, vaccines, over-the-counter medicines, cosmetics, foods, etc
- •(8) Has history of cardiac or vascular disease
- •(9) Shows clinically significant abnormalities in the clinical laboratory test result, which is related to hepatic function or renal function
- •(10) Had a fracture of the long bones or spine (except for fracture of digits or toes)
- •(11) Has history of hip surgery, severe hip dysplasia or serious hip injury
- •(12) Highly likely to be unable to complete the trial, judged by the Investigator
- •(13) Used any other IP or investigational medical device within 26 weeks (6 months) before study entry
- •(14) Inadequate as a patient for this trial for any other reason than above, considered by the Investigator
研究者
相似试验
进行中（未招募）
1 期
Follow-Up study in Previously Treated Children to investigate a new FVIII concentrateEUCTR2011-001785-17-PLOctapharma AG50
进行中（未招募）
1 期
Follow-Up study in Previously Treated Children to investigate a new FVIII concentrateSevere Haemophilia AMedDRA version: 14.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-001785-17-CZOctapharma AG60
进行中（未招募）
1 期
Follow-Up study in Previously Treated Children to investigate a new FVIII concentrateSevere Haemophilia AMedDRA version: 14.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-001785-17-FROctapharma AG60
进行中（未招募）
1 期
Follow-Up study in Previously Treated Children to investigate a new FVIII concentrateSevere Haemophilia AMedDRA version: 17.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2011-001785-17-GBOctapharma AG49
进行中（未招募）
不适用
Follow-Up study in Previously Treated Children to investigate a new FVIII concentrateEUCTR2011-001785-17-ROOctapharma AG50